-
1
-
-
0033863784
-
Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
-
Archer, R. H., C. Dykes, P. Gerondelis, A. Lloyd, P. Fay, R. C. Reichman, R. A. Bambara, and L. M. Demeter. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401.
-
(2000)
J. Virol.
, vol.74
, pp. 8390-8401
-
-
Archer, R.H.1
Dykes, C.2
Gerondelis, P.3
Lloyd, A.4
Fay, P.5
Reichman, R.C.6
Bambara, R.A.7
Demeter, L.M.8
-
2
-
-
0030691001
-
Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
-
Back, N. K., and B. Berkhout. 1997. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 41:2484-2491.
-
(1997)
Antimicrob. Agents Chemother.
, vol.41
, pp. 2484-2491
-
-
Back, N.K.1
Berkhout, B.2
-
3
-
-
0035104646
-
Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
-
Bleiber, G., M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti. 2001. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75:3291-3300.
-
(2001)
J. Virol.
, vol.75
, pp. 3291-3300
-
-
Bleiber, G.1
Munoz, M.2
Ciuffi, A.3
Meylan, P.4
Telenti, A.5
-
4
-
-
0034785773
-
Predicting the unpredictable: Transmission of drug-resistant HIV
-
Blower, S. M., A. N. Aschenbach, H. B. Gershengorn, and J. O. Kahn. 2001. Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. 7:1016-1020.
-
(2001)
Nat. Med.
, vol.7
, pp. 1016-1020
-
-
Blower, S.M.1
Aschenbach, A.N.2
Gershengorn, H.B.3
Kahn, J.O.4
-
5
-
-
0033615307
-
HIV-1 drug resistance in newly infected individuals
-
Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
-
(1999)
JAMA
, vol.282
, pp. 1135-1141
-
-
Boden, D.1
Hurley, A.2
Zhang, L.3
Cao, Y.4
Guo, Y.5
Jones, E.6
Tsay, J.7
Ip, J.8
Farthing, C.9
Limoli, K.10
Parkin, N.11
Markowitz, M.12
-
6
-
-
0030065565
-
Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
-
Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
-
(1996)
J. Gen. Virol.
, vol.77
, pp. 419-426
-
-
Borman, A.M.1
Paulous, S.2
Clavel, F.3
-
7
-
-
0036149707
-
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
-
Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76:1753-1761.
-
(2002)
J. Virol.
, vol.76
, pp. 1753-1761
-
-
Brenner, B.G.1
Routy, J.P.2
Petrella, M.3
Moisi, D.4
Oliveira, M.5
Detorio, M.6
Spira, B.7
Essabag, V.8
Conway, B.9
Lalonde, R.10
Sekaly, R.P.11
Wainberg, M.A.12
-
8
-
-
0030004944
-
Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
-
Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
-
(1996)
J. Virol.
, vol.70
, pp. 2146-2153
-
-
Caliendo, A.M.1
Savara, A.2
An, D.3
DeVore, K.4
Kaplan, J.C.5
D'Aquila, R.T.6
-
9
-
-
0035163687
-
Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
-
Cote, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
-
(2001)
J. Virol.
, vol.75
, pp. 589-594
-
-
Cote, H.C.1
Brumme, Z.L.2
Harrigan, P.R.3
-
10
-
-
0036147360
-
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease
-
Dauber, D. S., R. Ziermann, N. Parkin, D. J. Maly, S. Mahrus, J. L. Harris, J. A. Ellman, C. Petropoulos, and C. S. Craik. 2002. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J. Virol. 76:1359-1368.
-
(2002)
J. Virol.
, vol.76
, pp. 1359-1368
-
-
Dauber, D.S.1
Ziermann, R.2
Parkin, N.3
Maly, D.J.4
Mahrus, S.5
Harris, J.L.6
Ellman, J.A.7
Petropoulos, C.8
Craik, C.S.9
-
11
-
-
0035864943
-
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
-
Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
-
(2001)
N. Engl. J. Med.
, vol.344
, pp. 472-480
-
-
Deeks, S.G.1
Wrin, T.2
Liegler, T.3
Hoh, R.4
Hayden, M.5
Barbour, J.D.6
Hellmann, N.S.7
Petropoulos, C.J.8
McCune, J.M.9
Hellerstein, M.K.10
Grant, R.M.11
-
12
-
-
0035158709
-
Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
-
de Ronde, A., M. van Dooren, L. van Der Hoek, D. Bouwhuis, E. de Rooij, B. van Gemen, R. de Boer, and J. Goudsmit. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. 75:595-602.
-
(2001)
J. Virol.
, vol.75
, pp. 595-602
-
-
De Ronde, A.1
Van Dooren, M.2
Van Der Hoek, L.3
Bouwhuis, D.4
De Rooij, E.5
Van Gemen, B.6
De Boer, R.7
Goudsmit, J.8
-
13
-
-
0035811838
-
Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants
-
Dykes, C., K. Fox, A. Lloyd, M. Chiulli, E. Morse, and L. M. Demeter. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285:193-203.
-
(2001)
Virology
, vol.285
, pp. 193-203
-
-
Dykes, C.1
Fox, K.2
Lloyd, A.3
Chiulli, M.4
Morse, E.5
Demeter, L.M.6
-
14
-
-
0029840781
-
Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection
-
Ferbas, J., E. S. Daar, K. Grovit-Ferbas, W. J. Lech, R. Detels, J. V. Giorgi, and A. H. Kaplan. 1996. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J. Virol. 70:7285-7289.
-
(1996)
J. Virol.
, vol.70
, pp. 7285-7289
-
-
Ferbas, J.1
Daar, E.S.2
Grovit-Ferbas, K.3
Lech, W.J.4
Detels, R.5
Giorgi, J.V.6
Kaplan, A.H.7
-
15
-
-
0035923671
-
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
-
Garcia-Lerma, J. G., S. Nidtha, K. Blumoff, H. Weinstock, and W. Heneine. 2001. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98:13907-13912.
-
(2001)
Proc. Natl. Acad. Sci. USA
, vol.98
, pp. 13907-13912
-
-
Garcia-Lerma, J.G.1
Nidtha, S.2
Blumoff, K.3
Weinstock, H.4
Heneine, W.5
-
16
-
-
0037155193
-
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors
-
Gatanaga, H., Y. Suzuki, H. Tsang, K. Yoshimura, M. F. Kavlick, K. Nagashima, R. J. Gorelick, S. Mardy, C. Tang, M. F. Summers, and H. Mitsuya. 2002. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961.
-
(2002)
J. Biol. Chem.
, vol.277
, pp. 5952-5961
-
-
Gatanaga, H.1
Suzuki, Y.2
Tsang, H.3
Yoshimura, K.4
Kavlick, M.F.5
Nagashima, K.6
Gorelick, R.J.7
Mardy, S.8
Tang, C.9
Summers, M.F.10
Mitsuya, H.11
-
17
-
-
0034144024
-
Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase
-
Gotte, M., and M. A. Wainberg. 2000. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist. Update 3:30-38.
-
(2000)
Drug Resist. Update
, vol.3
, pp. 30-38
-
-
Gotte, M.1
Wainberg, M.A.2
-
18
-
-
0037055016
-
Time trends in primary HIV-1 drug resistance among recently infected persons
-
Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petropoulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
-
(2002)
JAMA
, vol.288
, pp. 181-188
-
-
Grant, R.M.1
Hecht, F.M.2
Warmerdam, M.3
Liu, L.4
Liegler, T.5
Petropoulos, C.J.6
Hellmann, N.S.7
Chesney, M.8
Busch, M.P.9
Kahn, J.O.10
-
19
-
-
0035857959
-
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda
-
Gray, R. H., M. J. Wawer, R. Brookmeyer, N. K. Sewankambo, D. Serwadda, F. Wabwire-Mangen, T. Lutalo, X. Li, T. vanCott, and T. C. Quinn. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357:1149-1153.
-
(2001)
Lancet
, vol.357
, pp. 1149-1153
-
-
Gray, R.H.1
Wawer, M.J.2
Brookmeyer, R.3
Sewankambo, N.K.4
Serwadda, D.5
Wabwire-Mangen, F.6
Lutalo, T.7
Li, X.8
VanCott, T.9
Quinn, T.C.10
-
20
-
-
0034987622
-
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy
-
Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vezinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
-
(2001)
J. Virol.
, vol.75
, pp. 6410-6417
-
-
Hance, A.J.1
Lemiale, V.2
Izopet, J.3
Lecossier, D.4
Joly, V.5
Massip, P.6
Mammano, F.7
Descamps, D.8
Brun-Vezinet, F.9
Clavel, F.10
-
21
-
-
0033762620
-
Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
-
Izopet, J., P. Massip, C. Souyris, K. Sandres, B. Puissant, M. Obadia, C. Pasquier, E. Bonnet, B. Marchou, and J. Puel. 2000. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14:2247-2255.
-
(2000)
AIDS
, vol.14
, pp. 2247-2255
-
-
Izopet, J.1
Massip, P.2
Souyris, C.3
Sandres, K.4
Puissant, B.5
Obadia, M.6
Pasquier, C.7
Bonnet, E.8
Marchou, B.9
Puel, J.10
-
22
-
-
0033834920
-
Virological and immunological characteristics of HIV treatment failure
-
Kaufmann, D., M. Munoz, G. Bleiber, S. Fleury, B. Lotti, R. Martinez, W. Pichler, P. Meylan, and A. Telenti. 2000. Virological and immunological characteristics of HIV treatment failure. AIDS 14:1767-1774.
-
(2000)
AIDS
, vol.14
, pp. 1767-1774
-
-
Kaufmann, D.1
Munoz, M.2
Bleiber, G.3
Fleury, S.4
Lotti, B.5
Martinez, R.6
Pichler, W.7
Meylan, P.8
Telenti, A.9
-
23
-
-
0036266750
-
Adaptive changes after human immunodeficiency virus type 1 transmission
-
Lawson, V. A., R. Oelrichs, C. Guillon, A. A. Imrie, D. A. Cooper, N. J. Deacon, and D. A. McPhee. 2002. Adaptive changes after human immunodeficiency virus type 1 transmission. AIDS Res. Hum. Retroviruses 18:545-556.
-
(2002)
AIDS Res. Hum. Retroviruses
, vol.18
, pp. 545-556
-
-
Lawson, V.A.1
Oelrichs, R.2
Guillon, C.3
Imrie, A.A.4
Cooper, D.A.5
Deacon, N.J.6
McPhee, D.A.7
-
24
-
-
0036888937
-
Virus population homogenization following acute human immunodeficiency virus type 1 infection
-
Learn, G. H., D. Muthui, S. J. Brodie, T. Zhu, K. Diem, J. I. Mullins, and L. Corey. 1959. 2002. Virus population homogenization following acute human immunodeficiency virus type 1 infection. J. Virol. 76:11953-11959.
-
(1959)
J. Virol.
, vol.76
, pp. 11953-11959
-
-
Learn, G.H.1
Muthui, D.2
Brodie, S.J.3
Zhu, T.4
Diem, K.5
Mullins, J.I.6
Corey, L.7
-
25
-
-
0033615280
-
Reduced antiretroviral drug susceptibility among patients with primary HIV infection
-
Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Hellmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
-
(1999)
JAMA
, vol.282
, pp. 1142-1149
-
-
Little, S.J.1
Daar, E.S.2
D'Aquila, R.T.3
Keiser, P.H.4
Connick, E.5
Whitcomb, J.M.6
Hellmann, N.S.7
Petropoulos, C.J.8
Sutton, L.9
Pitt, J.A.10
Rosenberg, E.S.11
Koup, R.A.12
Walker, B.D.13
Richman, D.D.14
-
26
-
-
0037043652
-
Antiretroviral-drug resistance among patients recently infected with HIV
-
Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 385-394
-
-
Little, S.J.1
Holte, S.2
Routy, J.P.3
Daar, E.S.4
Markowitz, M.5
Collier, A.C.6
Koup, R.A.7
Mellors, J.W.8
Connick, E.9
Conway, B.10
Kilby, M.11
Wang, L.12
Whitcomb, J.M.13
Hellmann, N.S.14
Richman, D.D.15
-
27
-
-
0033978489
-
Gender differences in HIV-1 diversity at time of infection
-
Long, E. M., H. L. Martin, Jr., J. K. Kreiss, S. M. Rainwater, L. Lavreys, D. J. Jackson, J. Rakwar, K. Mandaliya, and J. Overbaugh. 2000. Gender differences in HIV-1 diversity at time of infection. Nat. Med. 6:71-75.
-
(2000)
Nat. Med.
, vol.6
, pp. 71-75
-
-
Long, E.M.1
Martin H.L., Jr.2
Kreiss, J.K.3
Rainwater, S.M.4
Lavreys, L.5
Jackson, D.J.6
Rakwar, J.7
Mandaliya, K.8
Overbaugh, J.9
-
28
-
-
0031041174
-
Founder virus population related to route of virus transmission: A determinant of intrahost human immunodeficiency virus type 1 evolution?
-
Lukashov, V. V., and J. Goudsmit. 1997. Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? J. Virol. 71:2023-2030.
-
(1997)
J. Virol.
, vol.71
, pp. 2023-2030
-
-
Lukashov, V.V.1
Goudsmit, J.2
-
29
-
-
0031846317
-
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients
-
Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637.
-
(1998)
J. Virol.
, vol.72
, pp. 7632-7637
-
-
Mammano, F.1
Petit, C.2
Clavel, F.3
-
30
-
-
0033863985
-
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
-
Mammano, F., V. Trouplin, V. Zennou, and F. Clavel. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531.
-
(2000)
J. Virol.
, vol.74
, pp. 8524-8531
-
-
Mammano, F.1
Trouplin, V.2
Zennou, V.3
Clavel, F.4
-
31
-
-
0031897794
-
In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques
-
Miller, C. J., M. Marthas, J. Greenier, D. Lu, P. J. Dailey, and Y. Lu. 1998. In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J. Virol. 72:3248-3258.
-
(1998)
J. Virol.
, vol.72
, pp. 3248-3258
-
-
Miller, C.J.1
Marthas, M.2
Greenier, J.3
Lu, D.4
Dailey, P.J.5
Lu, Y.6
-
32
-
-
0344766077
-
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage
-
Morner, A., A. Bjorndal, J. Albert, V. N. Kewalramani, D. R. Littman, R. Inoue, R. Thorstensson, E. M. Fenyo, and E. Bjorling. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349.
-
(1999)
J. Virol.
, vol.73
, pp. 2343-2349
-
-
Morner, A.1
Bjorndal, A.2
Albert, J.3
Kewalramani, V.N.4
Littman, D.R.5
Inoue, R.6
Thorstensson, R.7
Fenyo, E.M.8
Bjorling, E.9
-
34
-
-
0033588178
-
Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors
-
Olsen, D. B., M. W. Stahlhut, C. A. Rutkowski, H. B. Schock, A. L. vanOlden, and L. C. Kuo. 1999. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J. Biol. Chem. 274:23699-23701.
-
(1999)
J. Biol. Chem.
, vol.274
, pp. 23699-23701
-
-
Olsen, D.B.1
Stahlhut, M.W.2
Rutkowski, C.A.3
Schock, H.B.4
VanOlden, A.L.5
Kuo, L.C.6
-
35
-
-
0034812843
-
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein
-
Peters, S., M. Munoz, S. Yerly, V. Sanchez-Merino, C. Lopez-Galindez, L. Perrin, B. Larder, D. Cmarko, S. Fakan, P. Meylan, and A. Telenti. 2001. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. J. Virol. 75:9644-9653.
-
(2001)
J. Virol.
, vol.75
, pp. 9644-9653
-
-
Peters, S.1
Munoz, M.2
Yerly, S.3
Sanchez-Merino, V.4
Lopez-Galindez, C.5
Perrin, L.6
Larder, B.7
Cmarko, D.8
Fakan, S.9
Meylan, P.10
Telenti, A.11
-
36
-
-
0034019566
-
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
-
Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
-
(2000)
Antimicrob. Agents Chemother.
, vol.44
, pp. 920-928
-
-
Petropoulos, C.J.1
Parkin, N.T.2
Limoli, K.L.3
Lie, Y.S.4
Wrin, T.5
Huang, W.6
Tian, H.7
Smith, D.8
Winslow, G.A.9
Capon, D.J.10
Whitcomb, J.M.11
-
37
-
-
0036784575
-
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease
-
Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
-
(2002)
J. Virol.
, vol.76
, pp. 10226-10233
-
-
Pettit, S.C.1
Henderson, G.J.2
Schiffer, C.A.3
Swanstrom, R.4
-
38
-
-
0033959515
-
Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy
-
Precious, H. M., H. F. Gunthard, J. K. Wong, R. T. D'Aquila, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, and A. J. Leigh Brown. 2000. Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 14:31-36.
-
(2000)
AIDS
, vol.14
, pp. 31-36
-
-
Precious, H.M.1
Gunthard, H.F.2
Wong, J.K.3
D'Aquila, R.T.4
Johnson, V.A.5
Kuritzkes, D.R.6
Richman, D.D.7
Leigh Brown, A.J.8
-
39
-
-
0036337934
-
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly
-
Resch, W., R. Ziermann, N. Parkin, A. Gamarnik, and R. Swanstrom. 2002. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76:8659-8666.
-
(2002)
J. Virol.
, vol.76
, pp. 8659-8666
-
-
Resch, W.1
Ziermann, R.2
Parkin, N.3
Gamarnik, A.4
Swanstrom, R.5
-
40
-
-
0034632745
-
HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
-
Robinson, L. H., R. E. Myers, B. W. Snowden, M. Tisdale, and E. D. Blair. 2000. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses 16:1149-1156.
-
(2000)
AIDS Res. Hum. Retroviruses
, vol.16
, pp. 1149-1156
-
-
Robinson, L.H.1
Myers, R.E.2
Snowden, B.W.3
Tisdale, M.4
Blair, E.D.5
-
41
-
-
0002035867
-
Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
-
Salomon, H., M. A. Wainberg, B. Brenner, Y. Quan, D. Rouleau, P. Cote, R. LeBlanc, E. Lefebvre, B. Spira, C. Tsoukas, R. P. Sekaly, B. Conway, D. Mayers, J. P. Routy, et al. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 14:F17-F23.
-
(2000)
AIDS
, vol.14
-
-
Salomon, H.1
Wainberg, M.A.2
Brenner, B.3
Quan, Y.4
Rouleau, D.5
Cote, P.6
LeBlanc, R.7
Lefebvre, E.8
Spira, B.9
Tsoukas, C.10
Sekaly, R.P.11
Conway, B.12
Mayers, D.13
Routy, J.P.14
-
42
-
-
0037178323
-
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals
-
Simon, V., J. Vanderhoeven, A. Hurley, B. Ramratnam, M. Louie, K. Dawson, N. Parkin, D. Boden, and M. Markowitz. 2002. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16:1511-1519.
-
(2002)
AIDS
, vol.16
, pp. 1511-1519
-
-
Simon, V.1
Vanderhoeven, J.2
Hurley, A.3
Ramratnam, B.4
Louie, M.5
Dawson, K.6
Parkin, N.7
Boden, D.8
Markowitz, M.9
-
43
-
-
0034948377
-
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
-
Stoddart, C. A., T. J. Liegler, F. Mammano, V. D. Linquist-Stepps, M. S. Hayden, S. G. Deeks, R. M. Grant, F. Clavel, and J. M. McCune. 2001. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat. Med. 7:712-718.
-
(2001)
Nat. Med.
, vol.7
, pp. 712-718
-
-
Stoddart, C.A.1
Liegler, T.J.2
Mammano, F.3
Linquist-Stepps, V.D.4
Hayden, M.S.5
Deeks, S.G.6
Grant, R.M.7
Clavel, F.8
McCune, J.M.9
-
44
-
-
0035814487
-
Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay
-
Vodros, D., C. Tscherning-Casper, L. Navea, D. Schols, E. De Clercq, and E. M. Fenyo. 2001. Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay. Virology 291:1-11.
-
(2001)
Virology
, vol.291
, pp. 1-11
-
-
Vodros, D.1
Tscherning-Casper, C.2
Navea, L.3
Schols, D.4
De Clercq, E.5
Fenyo, E.M.6
-
45
-
-
0003142266
-
Natural variation of replication capacity measurements in drug-naïve/susceptible HIV-1
-
Wrin, T., A. Gamarnik, N. Whitehurst, J. Beauchaine, J. M. Whitcomb, N. S. Hellmann, and C. J. Petropoulos. 2001. Natural variation of replication capacity measurements in drug-naïve/susceptible HIV-1. Antiviral Ther. 6:20.
-
(2001)
Antiviral Ther.
, vol.6
, pp. 20
-
-
Wrin, T.1
Gamarnik, A.2
Whitehurst, N.3
Beauchaine, J.4
Whitcomb, J.M.5
Hellmann, N.S.6
Petropoulos, C.J.7
-
46
-
-
0033612928
-
Transmission of antiretroviral-drug-resistant HIV-1 variants
-
Yerly, S., L. Kaiser, E. Race, J. P. Bru, F. Clavel, and L. Perrin. 1999. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733.
-
(1999)
Lancet
, vol.354
, pp. 729-733
-
-
Yerly, S.1
Kaiser, L.2
Race, E.3
Bru, J.P.4
Clavel, F.5
Perrin, L.6
-
47
-
-
0036100084
-
Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection
-
Zhang, Y. J., T. Hatziioannou, T. Zang, D. Braaten, J. Luban, S. P. Goff, and P. D. Bieniasz. 2002. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J. Virol. 76:6332-6343.
-
(2002)
J. Virol.
, vol.76
, pp. 6332-6343
-
-
Zhang, Y.J.1
Hatziioannou, T.2
Zang, T.3
Braaten, D.4
Luban, J.5
Goff, S.P.6
Bieniasz, P.D.7
-
48
-
-
0030769354
-
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
-
Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.
-
(1997)
J. Virol.
, vol.71
, pp. 6662-6670
-
-
Zhang, Y.M.1
Imamichi, H.2
Imamichi, T.3
Lane, H.C.4
Falloon, J.5
Vasudevachari, M.B.6
Salzman, N.P.7
|